A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia
一项针对复发或难治性急性髓系白血病患者的 I 期、单臂、开放标签、剂量递增、多中心研究，旨在评估 SAR445419（一种现成的、体外扩增的异基因自然杀伤细胞产品）的疗效。
期刊:Cancer Immunology Immunotherapy
影响因子:5.1
doi:10.1007/s00262-026-04333-y
Konopleva, Marina; Bhatt, Vijaya Raj; Mantzaris, Ioannis; Maiti, Abhishek; Gundabolu, Krishna; Schafer, Jolie; Jensen, Kyle; Saleem, Rao; Li, Yi; Drewniak, Agata; Bay, Pierre; Huh, Winston; Yildirim, Ozlem; Abbadessa, Giovanni; Cooley, Sarah; Daver, Naval
